Literature DB >> 10969858

Polymyalgia rheumatica and temporal arthritis.

T D Epperly1, K E Moore, J D Harrover.   

Abstract

Polymyalgia rheumatica and temporal arteritis are closely related inflammatory conditions that affect different cellular targets in genetically predisposed persons. Compared with temporal arteritis, polymyalgla rheumatica is much more common, affecting one in 200 persons older than 50 years. Temporal arteritis, however, is more dangerous and can lead to sudden blindness. The diagnosis of polymyalgia rheumatica is based on the presence of a clinical syndrome consisting of fever, nonspecific somatic complaints, pain and stiffness in the shoulder and pelvic girdles, and an elevated erythrocyte sedimentation rate. Temporal arteritis typically presents with many of the same findings as polymyalgia rheumatica, but patients also have headaches and tenderness to palpation over the involved artery. Arterial biopsy usually confirms the diagnosis of temporal arteritis. Early diagnosis and treatment of polymyalgia rheumatica or temporal arteritis can dramatically improve patients' lives and return them to previous functional status. Corticosteroid therapy provides rapid and dramatic improvement of the clinical features of both conditions. Therapy is generally continued for six to 24 months. Throughout treatment, clinical condition is assessed periodically. Patients are instructed to see their physician immediately if symptoms recur or they develop new headache, jaw claudication or visual problems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969858

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  3 in total

Review 1.  Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica.

Authors:  Thomas Nothnagl; Burkhard F Leeb
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  A disease activity score for polymyalgia rheumatica.

Authors:  B F Leeb; H A Bird
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

3.  EULAR response criteria for polymyalgia rheumatica: results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT).

Authors:  B F Leeb; H A Bird; G Nesher; I Andel; W Hueber; D Logar; C M Montecucco; J Rovensky; J Sautner; M Sonnenblick
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.